Literature DB >> 6738931

Detection of endometrial carcinoma and hyperplasia in asymptomatic women.

L G Koss, K Schreiber, S G Oberlander, H F Moussouris, M Lesser.   

Abstract

Occult endometrial carcinoma is a detectable disease using commercially available sampling devices and cytohistologic techniques. A cohort of 2586 asymptomatic women (98% past the age of 45, 78% caucasian) was screened. Of these women, 1567 were screened twice, and 187 were screened three times. The prevalence and incidence rates of endometrial carcinoma, as defined in the present study, including four missed cases, were 6.96 per 1000 and 1.71 per 1000 women years, respectively. The prevalence rate was 7.38 per 1000 for caucasian women and 5.40 per 1000 for women of other races. An epidemiologic evaluation suggested that the onset of menopause past the age of 49 was the only statistically significant risk factor, whereas race, parity, estrogen intake, and obesity, as calculated by the Quetelet index, were not statistically significant. The present study strongly suggests that in asymptomatic women past the age of 50, endometrial hyperplasia does not necessarily precede or accompany the development of endometrial carcinoma. Two distinct mechanisms may be responsible for the onset of endometrial cancer: endometrial hyperplasia occurring in the symptomatic and younger woman; and endometrial adenocarcinoma occurring ab initio in the older patient.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6738931

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  11 in total

1.  Who needs an endometrial biopsy?

Authors:  Sheri-Lee Samson; Donna Gilmour
Journal:  Can Fam Physician       Date:  2002-05       Impact factor: 3.275

2.  The periodic health examination: 2. 1987 update. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1988-04-01       Impact factor: 8.262

3.  Endometrial carcinoma: feasibility of case-finding in a family physician's office.

Authors:  G L Gray; P A Ellison; M S Shafir
Journal:  CMAJ       Date:  1988-01-15       Impact factor: 8.262

4.  Mathematical models and scientific reality in occurrence rates for disease.

Authors:  A R Feinstein; C K Chan; J M Esdaile; R I Horwitz; M J McFarlane; C K Wells
Journal:  Am J Public Health       Date:  1989-09       Impact factor: 9.308

5.  Adjuvant treatment with tamoxifen. Side effects may have been overstated.

Authors:  M Baum; J Cuzick
Journal:  BMJ       Date:  1996-04-20

Review 6.  Pathophysiology and management of endometrial hyperplasia and carcinoma.

Authors:  Y S Fu; J C Gambone; J S Berek
Journal:  West J Med       Date:  1990-07

7.  Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium.

Authors:  E Jason Gates; Lawrence Hirschfield; Roland P Matthews; O W Stephanie Yap
Journal:  J Natl Med Assoc       Date:  2006-11       Impact factor: 1.798

8.  Experimental genital trichomoniasis in the squirrel monkey (Saimiri sciureus).

Authors:  W A Gardner; D E Culberson; J M Scimeca; A G Brady; F F Pindak; C R Abee
Journal:  Genitourin Med       Date:  1987-06

9.  Tamoxifen--the treatment of choice. Why look for alternatives?

Authors:  M Baum
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

Review 10.  Complications and challenges associated with polycystic ovary syndrome: current perspectives.

Authors:  Stefano Palomba; Susanna Santagni; Angela Falbo; Giovanni Battista La Sala
Journal:  Int J Womens Health       Date:  2015-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.